Alimera Sciences, Inc. (ALIM)

$3.435

-0.41 (-10.55%)
Rating:
Recommendation:
Buy
Symbol ALIM
Price $3.435
Beta 1.377
Volume Avg. 0.01M
Market Cap 24.074M
Shares () -
52 Week Range 3.36-7.92
1y Target Est -
DCF Unlevered ALIM DCF ->
DCF Levered ALIM LDCF ->
ROE 177.15% Strong Buy
ROA -42.44% Strong Sell
Operating Margin -
Debt / Equity -340.23% Strong Sell
P/E -3.55 Strong Sell
P/B -1.33 Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ALIM news


Mr. Richard Eiswirth
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.